Welcome To SteroidScience.org

A comprehensive resource of relevant human studies of anabolic steroids for bodybuilders, athletes and students.
Showing posts with label Stanozolol (Winstrol). Show all posts
Showing posts with label Stanozolol (Winstrol). Show all posts

Anabolic androgenic steroids and aggression: studies using animal models.

. Sunday, 7 September 2008
0 comments

Ann N Y Acad Sci. 2004 Dec;1036:399-415.

Anabolic androgenic steroids and aggression: studies using animal models.

McGinnis MY.

Department of Biology, University of Texas at San Antonio, 6900 North Loop 1604
West, San Antonio, Texas 78249, USA. mmcginnis@utsa.edu

The use of anabolic androgenic steroids (AASs) has escalated in teenagers and is
associated with increased violence. Adolescent exposure to chronic high levels of
AASs is of particular concern because puberty is a hormonally sensitive period
during which neural circuitry for adult male patterns of behavior develop. Thus,
teenage AAS use may have long-term repercussions on the potential for displaying
aggression and violence. Animal models have contributed valuable information on
the effects of AAS use. For example, studies in rodents confirmed that exposure
to the AASs testosterone and nandrolone, but not stanozolol, does indeed increase
aggression. A side effect of AAS use reported in humans is "'roid rage,"
characterized by indiscriminate and unprovoked aggression. Results of animal
studies demonstrated that pubertal rats receiving AASs respond appropriately to
social cues as they are more aggressive toward intact males than are castrates.
Also, testosterone-treated males recognize appropriate environmental cues as they
are most aggressive in their home cage. Thus, adolescent AAS exposure increases
aggressive behaviors, but does not induce indiscriminate aggression. To assess
whether AAS exposure increases aggression after provocation, rats were tested
following a mild tail-pinch. In adolescent males, provocation increased
aggression after withdrawal from testosterone, nandrolone, and stanozolol, an
effect which persisted for many weeks. The data suggest that AASs sensitize
animals to their surroundings and lower the threshold to respond to provocation
with aggression. Thus, in humans, pubertal AAS exposure may not cause violent
behaviors, but may increase the likelihood that aggressive acts will result in
violence. This may persist into adulthood.

Peliosis: a morphologic curiosity becomes an iatrogenic problem.

. Wednesday, 13 August 2008
0 comments

Hum Pathol. 1978 May;9(3):331-40.

Peliosis: a morphologic curiosity becomes an iatrogenic problem.

Taxy JB.

Peliosis is a morphologic entity describing a condition of blood filled spaces,
most frequently occurring in the liver. In recent years it has evolved from an
anatomic curiosity seen at autopsy to a potential clinical problem in view of its
association with the administration of anabolic steroid hormones. The
pathogenesis and predilection of peliosis for the liver remain unexplained. This
article reports five patients with peliosis, four with splenic involvement, all
but one of whom received an anabolic steroid preparation. One patient died as a
result of rupture of the splenic peliotic spaces. The diagnosis in three cases
was established on the basis of surgical material, i.e., liver biopsy or
splenectomy. An increased awareness of peliosis in patients at risk, as well as
an appreciation for the histopathologic changes in less advanced cases, may
become an important issue for the surgical pathologist.

Effects of use of anabolic steroids on the masticatory system: a pilot study.

. Friday, 11 July 2008
0 comments

J Oral Sci. 2008 Mar;50(1):19-24.

Effects of use of anabolic steroids on the masticatory system: a pilot study.

Barros TS, Santos MB, Shinozaki EB, Santos JF, Marchini L.

Department of Dentistry, University of Vale do Paraíba - UNIVAP, São José dos
Campos, Brazil.

The use of androgenic anabolic steroids (AAS) has increased significantly among
athletes in Brazil and other countries. These drugs alter the physiological
behavior of bone and muscles, also affecting these structures in masticatory
system. This paper aims to evaluate bone and dental changes in users of AAS, as
well as the incidence of temporomandibular dysfunction (TMD), compared to
athletes not using AAS. Eight athletes were equally divided in two groups, AAS
users and non-users. The groups were evaluated using Helkimo index, McNamara
cephalometric tracing and cast analysis. The AAS users presented more intense TMD
signs and symptoms (Di total value, P = 0.096, Mann-Whitney test), increased
cephalometric measures (Co-A, P = 0.020, Mann-Whitney test) and Angle Class II
malocclusion, compared to the non-users. These results suggested that the use of
AAS alters masticatory structures and increases the incidence of TMD.

Ischemic stroke related to anabolic abuse.

.
0 comments

Clin Neuropharmacol. 2008 Mar-Apr;31(2):80-5.

Ischemic stroke related to anabolic abuse.

Santamarina RD, Besocke AG, Romano LM, Ioli PL, Gonorazky SE.

Neurology Department, Hospital Privado de Comunidad, Mar del Plata, Argentina.
rsantamarina@sna.org.ar.

Anabolic-androgenic steroid (AAS) abuse increased in recent years, and it is
associated with numerous adverse effects. Few reports on ischemic stroke related
to anabolic steroid abuse have been published. We report a case of a 26-year-old
male amateur athlete who suffered a posterior territory ischemic stroke. No
abnormalities were found in angiography and echocardiography studies, neither in
hemostatic profile. His only significant risk factor was nonmedical use of
stanozolol, an anabolic steroid. Anabolic steroids are capable of increasing
vascular tone, arterial tension, and platelet aggregation; therefore, they are
prone to produce atherothrombotic phenomena. Because of young people's widespread
use of anabolic steroids, physicians should be aware of this kind of
complication.

Prevalence of the use of anabolic agents among strength training apprentices in Porto Alegre, RS

.
0 comments

Arq Bras Endocrinol Metabol. 2007 Feb;51(1):104-10.

[Prevalence of the use of anabolic agents among strength training apprentices in
Porto Alegre, RS]

[Article in Portuguese]

Silva PR, Machado LC Jr, Figueiredo VC, Cioffi AP, Prestes MC, Czepielewski MA.

Faculdade de Medicina, UFRGS, RS.

This study aimed to determine through a questionnaire applied to interviewers,
the current or past use of anabolic androgenic steroids (AAS), as well as other
hormones (OH), and other medicines (OM), food supplement and illicit drugs among
strength training apprentices in the city of Porto Alegre, RS. We interviewed 288
subjects draw from a sample of 13 gyms. The prevalence of current and past use of
AAS was about 11.1% (32/288), OH 5.2% (16/288) and OM 4.2% (12/288). The most
used AAS were nandrolone and stanozolol; the OH were gonadotropin,
triiodothyronine (T3) and OM, like lipostabil, diuretics and veterinary medicines
(Monovin E). The most frequent side-effects were behavioral such as humor
oscillation, irritability and hostility, and endocrine disturbances such as acne
and increased or decreased libido. When analyzed together with other hormones in
a variable named "hormonal agents" (AH), AAS presented a statistical difference
(p< 0.05) among genders considering that the most frequent use of AH occurred
among men and those who consume food supplements. The comparison of these
findings to other national and international results is difficult due to the
epidemiological design. Even if it is considered, the observed prevalence
suggests that preventive attitudes as well as special care in the orientation and
education of this population must be taken.

Lupus nephritis remission, albeit with positive anti-doping test.

.
0 comments

Joint Bone Spine. 2007 Jan;74(1):96-7. Epub 2006 Feb 17.

Lupus nephritis remission, albeit with positive anti-doping test.

Jakez-Ocampo J, Richaud-Patin Y, Llorente L.

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas
y Nutrición, Salvador Zubirán, Vasco de Quiroga 15, Tlalpan 14000, México City,
México. lllyrp@quetzal.innsz.mx

A 39-year-old woman developed systemic lupus erythematosus with nephropathy after
a holiday in Jamaica. She was prescribed with prednisone, azathioprine and
aspirin. As she was obsessed with aesthetic procedures, she decided not to take
the prescription. Instead, she took her bodybuilding trainer's advice of one
intramuscular injection of stanozolol for 10 weeks in order to increase her
gluteus area. One week after finishing the latter regimen, there was no disease
activity. Whether lupus remission in this patient was spontaneous or a
consequence of stanozolol administration will remain a riddle for this fortunate
outcome.

Anabolic steroid and gonadotropin releasing hormone analog combined treatment increased pubertal height gain and adult height in two children who entered puberty with short stature.

.
0 comments

J Pediatr Endocrinol Metab. 2006 Sep;19(9):1125-31.

Anabolic steroid and gonadotropin releasing hormone analog combined treatment
increased pubertal height gain and adult height in two children who entered
puberty with short stature.

Satoh M, Yokoya S.

First Department of Pediatrics, Toho University School of Medicine, Japan.
satomari@med.toho-u.ac.jp

We studied the effect of gonadal suppression treatment in combination with
anabolic steroid on pubertal height gain and adult height in two children who
entered puberty with short stature. Patient 1 was a female with idiopathic short
stature. She received combined treatment with an anabolic steroid (stanozolol)
and a gonadotropin releasing hormone analog (leuprorelin acetate). Her pubertal
height gain was 28.5 cm, which is greater than that in normal height girls (20-25
cm). Patient 2 was a male with Aarskog syndrome. Although his growth hormone (GH)
secretion was normal, he received GH treatment. Since GH administration did not
accelerate his growth, he received combined treatment with stanozolol and
leuprorelin acetate. His pubertal height gain was 27.0 cm, which is greater than
that observed in GH deficient boys treated with GH alone (21.9 cm). Combined
treatment with stanozolol and leuprorelin acetate appears to be effective in
increasing pubertal height gain and adult height in children who enter puberty
with short stature.

Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids.

.
0 comments

Eur J Clin Invest. 2006 Jul;36(7):483-8.

Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids.

Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, Davies JS.

Department of Endocrinology, University Hospital of Wales, Heath Park, Cardiff
CF14 4XW, Wales, UK. laneha@cf.ac.uk

BACKGROUND: Anabolic androgenic steroids are used by some bodybuilders to enhance
performance. While the cardiovascular implications of supraphysiological androgen
levels requires further clarification, use is associated with sudden death, left
ventricular hypertrophy, thrombo-embolism and cerebro-vascular events.

MATERIALS
AND METHODS:
To further understand the effect of androgenic anabolic steroid
abuse on vascular function, this study assessed vascular stiffness (pulse-wave
analysis) and cardiovascular risk factors in 28 male, bodybuilding subjects, of
whom ten were actively receiving anabolic agents (group A; 26.4 +/- 7.2 years)
and eight had undergone a 3-month "wash-out" period (group B; 32.1 +/- 7.1
years). The remaining ten bodybuilding subjects (group C; 24.4 +/- 4.4 years)
denied any past use of anabolic steroids or other performance enhancing drugs.
Comparisons were made with ten sedentary male controls (group D, 29.3 +/- 4.7
years).

RESULTS: Endothelial independent dilatation in response to glycerol
trinitrate was significantly impaired in the group currently using anabolic
steroids (group A) compared with the other three groups [A (5.63 +/- 3.24%)
versus; B (11.10 +/- 4.91%), C (17.88 +/- 9.2%) and D (14.46 +/- 3.9%), P <
0.0005, respectively], whereas no significant differences in
endothelial-dependent dilatation were detected between the groups [A (5.0 +/-
3.0%), B (7.4 +/- 3.4%), C (9.6 +/- 4.5%) and D (8.2 +/- 3.3%), P < 0.059,
respectively].

CONCLUSIONS: Previous studies described a decline in vascular
reactivity occurring in bodybuilding subjects which is independent of anabolic
steroid use and may result from smooth muscle hypertrophy with increased vascular
stiffness. This study revealed impaired vascular reactivity associated with
anabolic agents and that improvement in vascular function may occur following
their discontinuation.

Stacking anabolic androgenic steroids (AAS) during puberty in rats: a neuroendocrine and behavioral assessment.

.
0 comments

Pharmacol Biochem Behav. 2006 Mar;83(3):410-9. Epub 2006 Apr 17.

Stacking anabolic androgenic steroids (AAS) during puberty in rats: a
neuroendocrine and behavioral assessment.

Wesson DW, McGinnis MY.

The University of Texas at San Antonio, Department of Biology, 6900 North Loop
1604 West, San Antonio, TX 78249, USA.

Anabolic androgenic steroid (AAS) abuse is increasing in teenagers. We examined
the effects of stacked AAS in adolescent male rats. Stacking, in which multiple
AAS are taken simultaneously, is commonly employed by humans. Beginning at
puberty gonadally intact male rats received testosterone, nandrolone, or
stanozolol. Additional groups received stacked AAS: testosterone + stanozolol,
nandrolone + stanozolol, or nandrolone + testosterone. Injections continued
during tests for sexual behavior, vocalizations, scent marking, partner
preference, aggression and fertility. Body and reproductive tissue weights were
taken. Sexual and aggressive behaviors were increased by testosterone yet
inhibited by stanozolol; nandrolone had no effect. Stacking testosterone with
stanozolol prevented the inhibitory effects of stanozolol. Body weight was
decreased by testosterone and all stacked AAS. Cell nuclear androgen receptor
binding in brain was significantly increased in nandrolone males and decreased in
stanozolol males; testosterone males were slightly higher than controls. Androgen
receptors in stacked groups were intermediate between individual AAS suggesting
that stanozolol competed with other AAS for androgen receptors despite its low
affinity. The results indicate that stacking AAS influences the effects of
individual AAS on behavioral and endocrine measures, and levels of androgen
receptor occupation are not directly correlated with AAS effects on behavior.

Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen.

.
0 comments

Leuk Res. 2006 Aug;30(8):935-42. Epub 2006 Jan 30.

Successful treatment of primary refractory anemia with a combination regimen of
all-trans retinoic acid, calcitriol, and androgen.

Zhang W, Zhou F, Cao X, Cheng Y, He A, Liu J, Ma X, Chen G.

Department of Clinical Hematology, Affiliated No. 2 Hospital, Xi'an Jiaotong
University, 157 West Five Road, Xi'an 710004, PR China.
alisantra0351@yahoo.com.cn

We investigated the efficacy and safety of a combination regimen in 63 patients
with primary refractory anemia (RA). The daily treatment protocol comprised
all-trans retinoic acid (ATRA) (30 mg/m(2)), calcitriol (0.1 microg/m(2)), and
androgen (stanozolol 3mg/m(2), or danazol 300 mg/m(2)) in three separate doses
for eight consecutive weeks. Hematologic improvement was observed in 43 (68.3%)
patients. The treatment administered was generally well tolerated, with no severe
regimen-related toxicity. The overall survival rates at 3 and 5 years were 68.72%
and 53.18%, respectively. These results indicate that this combination regimen is
an effective and well-tolerated treatment for patients with RA.

Synchronous bilateral ductal carcinoma in situ of the male breast associated with gynecomastia in a 30-year-old patient following repeated injections of stanozolol.

.
0 comments

Breast Cancer Res Treat. 2006 May;97(2):173-6. Epub 2005 Dec 3.

Erratum in:
    Breast Cancer Res Treat. 2006 May;97(2):177. Melcher, A [corrected to Melcher,
Gian A].

Synchronous bilateral ductal carcinoma in situ of the male breast associated with
gynecomastia in a 30-year-old patient following repeated injections of
stanozolol.

Staerkle RF, Lenzlinger PM, Suter SL, Varga Z, Melcher GA.

Department of Surgery, Spital Uster, Uster, Switzerland.

We report a rare case of synchronous bilateral and multifocal ductal carcinoma in
situ (DCIS) in a 30-year-old patient operated on for gynecomastia following
repeated injections of stanozolol, a non-aromatizable androgen. The familial
medical history was negative for breast cancer and work-up of serum hormone
levels was normal. The patient underwent a modified radical mastectomy without
axilla dissection 6 weeks following the primary procedure and recovered
uneventfully. The role of synthetic androgens in the development of male breast
neoplasia warrants further scrutiny.

Management of male sterility in patients taking anabolic steroids

.
0 comments

 Arch Esp Urol. 2005 Apr;58(3):241-4.

[Management of male sterility in patients taking anabolic steroids]

[Article in Spanish]

de la Torre Abril L, Ramada Benlloch F, Sánchez Ballester F, Ordoño Domínguez F,
Ulises Juan Escudero J, Navalón Verdejo P, López Alcina E, Ramos de Campos M,
Zaragoza Orts J.

Servicio de Urología, Consorcio Hospital General Universitario, Valencia, España.
Luitorrr@hotmail.com

OBJECTIVES/METHODS: To review the incidence of male infertility secondary to
intake of anabolic products and our experience and outcomes with treatment. There
is a variety of such substances (testosterone, nandrolone, stanozolol, etc.) in
their intake may be unique or combinations, both orally or parenterally.
Comparisons between patients and case series are difficult because of the hiding
of this practice and various consumption practices and doses employed.
RESULTS/CONCLUSIONS: Most of the patients recover normal spermatogenesis does by
stopping intake of anabolic substances. The period of time until recovery is 6.35
months. Patients not recovering after six months were given tamoxifen 20
mg/24-hour, if having a normal or inhibited hypothalamus-hypophysis axis.
Duration of abuse, doses, and anarchical consumption maderesponse to treatment
with antiestrogen drugs or gonadotropins unpredictable in patients not responding
to conservative treatment.

Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature.

.
0 comments

Br J Sports Med. 2005 May;39(5):e27.

Hepatocellular adenomas associated with anabolic androgenic steroid abuse in
bodybuilders: a report of two cases and a review of the literature.

Socas L, Zumbado M, Pérez-Luzardo O, Ramos A, Pérez C, Hernández JR, Boada LD.

Department of Radiology, Cajal Clinical Centre, Las Palmas de Gran Canaria,
Canary Islands, Spain.

Anabolic androgenic steroids (AAS) are used illicitly at high doses by
bodybuilders. The misuse of these drugs is associated with serious adverse
effects to the liver, including cellular adenomas and adenocarcinomas. We report
two very different cases of adult male bodybuilders who developed hepatocellular
adenomas following AAS abuse. The first patient was asymptomatic but had two
large liver lesions which were detected by ultrasound studies after routine
medical examination. The second patient was admitted to our hospital with acute
renal failure and ultrasound (US) studies showed mild hepatomegaly with several
very close hyperecogenic nodules in liver, concordant with adenomas at first
diagnosis. In both cases the patients have evolved favourably and the tumours
have shown a tendency to regress after the withdrawal of AAS. The cases presented
here are rare but may well be suggestive of the natural course of AAS induced
hepatocellular adenomas. In conclusion, sportsmen taking AAS should be considered
as a group at risk of developing hepatic sex hormone related tumours.
Consequently, they should be carefully and periodically monitored with US
studies. In any case, despite the size of the tumours detected in these two
cases, the possibility of spontaneous tumour regression must also be taken in
account.

Nonhealing ulcer secondary to factor V Leiden mutation and cryofibrinogenemia.

.
0 comments

J Am Acad Dermatol. 2004 Nov;51(5 Suppl):S194-6.

Erratum in:
    J Am Acad Dermatol. 2004 Dec;51(6):1040.

Nonhealing ulcer secondary to factor V Leiden mutation and cryofibrinogenemia.

Barrio VR, Sanfilippo AM, Malone JC, Callen JP.

Department of Medicine, Division of Dermatology, University of Louisville School
of Medicine, Louisville, Kentucky 40202, USA.

Factor V Leiden is the most common genetic thrombophilia in people of European
descent, and is important to recognize as it can have significant implications in
dermatology. We report a case of a 30-year-old man who presented for evaluation
and treatment of a chronic ulceration on the site of his stump following a below
the knee amputation which had been performed for non-healing ulcerations. Despite
a variety of treatments, his ulcer persisted. He was referred to a dermatologist
who performed a biopsy that was interpreted ass non-specific, and treatment was
started for pyoderma gangrenosum. Further investigation revealed a homozygous
factor V Leiden mutation and cryofibrinogenemia. He was tapered off of the
methylprednisolone and was improving on stanozolol. He healed well after surgery
and no new ulcerations have developed. This case highlights the importance of
considering this mutation in a non-healing leg ulcer.

Oxandrolone treatment of childhood hereditary angioedema.

.
0 comments

Ann Allergy Asthma Immunol. 2004 Mar;92(3):377-8.

Oxandrolone treatment of childhood hereditary angioedema.

Church JA.

Division of Clinical Immunology and Allergy, Department of Pediatrics, Childrens
Hospital Los Angeles and Keck of School of Medicine, The University of Southern
California, Los Angeles, California 90027, USA. jchurch@chla.usc.edu

BACKGROUND: The virilizing effects of danazol, stanozolol, and methyltestosterone
significantly restrict the usefulness of these agents in the treatment of
children with hereditary angioedema (HAE). Oxandrolone is a synthetic anabolic
steroid with limited virilizing effects that has been used in a variety of
pediatric conditions and has an acceptable safety profile.

OBJECTIVE: To report
the effective use of oxandrolone in a 6-year-old boy with recurrent,
life-threatening episodes of angioedema.

METHODS: Oxandrolone was administered at
a dose of 0.1 mg/kg per day. Symptoms and laboratory findings were evaluated by
parental report and laboratory analysis of serum C1 esterase inhibitor and C4
levels, respectively.

RESULTS: Oxandrolone therapy resulted in a marked reduction
in clinical episodes and normalization of serum complement levels; cessation of
oxandrolone therapy resulted in recurrence of symptoms and decreased complement
levels. However, early signs of virilization were noted.

CONCLUSIONS: Oxandrolone
treatment was associated with significant clinical and laboratory evidence of a
therapeutic effect in a prepuberal boy with HAE. It is imperative to treat HAE
with the lowest dose of oxandrolone that controls life-threatening episodes of
angioedema

The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology.

.
0 comments

Eur J Clin Pharmacol. 2003 Nov;59(8-9):571-7. Epub 2003 Sep 12.

The anti-doping hot-line, a means to capture the abuse of doping agents in the
Swedish society and a new service function in clinical pharmacology.

Eklöf AC, Thurelius AM, Garle M, Rane A, Sjöqvist F.

Department of Clinical Pharmacology, Huddinge University Hospital, 14185
Stockholm, Sweden.

With the support of the Swedish National Institute of Health a national
information service was started in 1993 aiming to capture the abuse of doping
agents in the general public. It was organized as a telephone service, called the
Anti-Doping Hot-Line, from our department and managed by trained nurses
co-operating with clinical pharmacologists. Important information collected about
all callers (anonymous) was: date of call, its origin, category of caller, doping
experience and main question being asked. Abusers were asked about their age,
sex, affiliation, abused drug(s), duration of abuse, habit of administration and
adverse reactions (ADRs). Between October 1993 and December 2000 25,835 calls
were received with a peak during spring and autumn. Most calls (12,400) came from
non-abusers, 60% being males. Callers connected with gyms represented the largest
group (30%). Most calls about specific drugs concerned anabolic androgenic
steroids (AAS). Other drugs or products included ephedrine, clenbuterol and
creatine. The most commonly abused anabolic steroids were testosterone,
nandrolone-decanoate, methandienone and stanozolol. The ten most commonly
reported ADRs of AAS were aggressiveness (835), depression (829), acne (770),
gynecomastia (637), anxiousness (637), potency problems (413), testicular atrophy
(404), sleep disorders (328), fluid retention (318) and mood disturbances (302).
Female side effects included menstruation disturbances, hair growth in the face,
lower voice and enlarged clitoris. During the period 1996-200, totally 4339
persons reported about 10,800 side effects. This figure should be compared with
the very low number of ADRs (27) reported by prescribers to the Swedish ADR
committee during the same period. Abuse of doping agents appears to be a new
public health problem that needs detection, medical care and prevention.

Growth-promoting effect of recombinant human growth hormone and stanozolol in girls with Turner syndrome.

.
0 comments

J Tongji Med Univ. 1999;19(1):63-5.

Growth-promoting effect of recombinant human growth hormone and stanozolol in
girls with Turner syndrome.

Fang J, Ning C, Shu D, Wei H, Lin H, Wang M.

Department of Pediatrics, Tongji Hospital, Tongji Medical University, Wuhan
430030.

Ten girls with Turner syndrome were treated with a combination therapy of
recombinant human growth hormone (R-hGH) and low dose stanozolol for a period of
8 to 36 months. The results showed that when compared with the growth rate before
the treatment, the growth rates after treatment with R-hGH and stanozolol showed
a sustained increase, reaching 9.0 +/- 1.9 cm/year during the first year of
treatment; the height age increase by 2.5 +/- 0.8 years while the bone age
increase were 1.0 +/- 0.7 years; and the predicted final adult height at the end
of the first year of the treatment increased to 149.4 +/- 6.1 cm compared to
their original mean of 142.8 +/- 4.2 cm. We are led to conclude that therapy with
R-hGH in combination with stanozolol can increase the growth velocity and
significantly increase the predicted adult height of children with Turner
syndrome.

Species, sex and inter-individual differences in DNA repair induced by nine sex steroids in primary cultures of rat and human hepatocytes.

.
0 comments

Mutat Res. 2003 Apr 20;536(1-2):69-78.

Species, sex and inter-individual differences in DNA repair induced by nine sex
steroids in primary cultures of rat and human hepatocytes.

Martelli A, Mattioli F, Angiola M, Reimann R, Brambilla G.

Department of Internal Medicine, Division of Clinical Pharmacology and
Toxicology, University of Genoa, Viale Benedetto XV 2, I-16132, Genoa, Italy.

Sex steroids, due to the generally negative responses observed in routinely
employed standard genotoxicity assays, are considered epigenetic carcinogens.
Some doubts on this conviction are raised by the results of recent studies
providing evidence that cyproterone acetate and two structural analogues,
chlormadinone acetate and megestrol acetate, are genotoxic in female rats but
only for the liver, and in primary human hepatocytes from donors of both genders.
The experimental evidence suggests that the metabolic activation of these
molecules to reactive species and the consequent formation of DNA adducts occur
only in the intact hepatocyte. Since the possibility that other sex steroids
cause a liver-specific genotoxic effect cannot be ruled out a priori, we
investigated nine drugs of this family for their ability to induce DNA repair
synthesis in primary cultures of rat and human hepatocytes. Each steroid was
tested in cultures from at least two male and two female donors of each species.
Hepatocytes were exposed for 20h to sub-toxic concentrations ranging from 1 to 50
micro M, and DNA repair induction was measured by quantitative autoradiography.
In primary rat hepatocytes, induction of DNA repair indicative of a frankly
positive response was detected in cultures from: 2/2 males and 3/3 females with
drospirenone, 2/2 males and 1/2 females with ethinylestradiol, 1/2 males and 1/2
females with oxymetholone, 1/2 males with norethisterone, 1/4 females with
progesterone, and 1/4 males with methyltestosterone. Consistent negative
responses were obtained with testosterone and stanozolol. A few inconclusive
responses were observed in rat hepatocytes exposed to progesterone,
medroxyprogesterone, norethisterone, methyltestosterone and oxymetholone. In
contrast, under the same experimental conditions the nine sex steroids provided
frankly negative responses in the large majority of cultures of primary
hepatocytes from both male and female human donors; the only exceptions being the
inconclusive responses obtained in cultures from two of the donors exposed to
norethisterone and to ethinylestradiol, and from one of the donors exposed to
testosterone, methyltestosterone, and stanozolol. These results and previous
findings concerning cyproterone and its structural analogues suggest that sex
steroids differ for their ability to induce DNA repair, and that their
genotoxicity may be: (i) different in rat and human hepatocytes, (ii) dependent
on the sex of the donor, and (iii) affected by inter-individual variability.

Androgenic/Anabolic steroid-induced toxic hepatitis.

.
0 comments

J Clin Gastroenterol. 2002 Oct;35(4):350-2.

Androgenic/Anabolic steroid-induced toxic hepatitis.

Stimac D, Milić S, Dintinjana RD, Kovac D, Ristić S.

Division of Gastroenterology, Department of Internal Medicine, Clinical Hospital
Center Rijeka, Rijeka, Croatia. davor.stimac@ri.hinet.hr

Athletes and bodybuilders often misuse androgenic/anabolic steroids. When used in
therapeutic doses, these drugs produce clinical jaundice in just a small number
of recipients. We present a 26-year-old male bodybuilder who self-administered
high doses of androgenic/anabolic steroids that induced liver damage. One month
before admission to the hospital, he used testosterone enanthate (500 mg
intramuscularly, twice weekly), stanozolol (40 mg/d), and methylandrostenediol
(30 mg/d by mouth, for 5 weeks). On admission, his bilirubin level was 470
micromol/L (direct, 360 micromol/L), his aspartate aminotransferase (AST) level
was 5,870 IU/L, his alanine aminotransferase (ALT) level was 10,580 IU/L, his
alkaline phosphatase (ALP) level was 152 IU/L, his gamma-glutamyl-transpeptidase
level was 140 IU/L, his albumin level was 27.6 g/L, and his prothrombin time was
29%. During the patient's prolonged hospitalization, multiple tests and liver
biopsy were performed, showing only toxic hepatic lesions. The patient was
provided with supportive medical treatment. Clinical signs and laboratory
findings improved substantially 12 weeks after the patient discontinued
androgenic/anabolic steroids. The reasons for presenting this case were the much
higher values of AST and ALT levels than reported in other studies, although the
values of bilirubin and ALP were similar to those found in the literature. To our
knowledge, it is the first case of toxic hepatitis induced by androgenic/anabolic
steroids with predominantly hepatocellular necrosis instead of intrahepatic
cholestasis.

'Skin popping' ulceration in an HIV patient. Successful treatment with antiretroviral drugs and stanozolol.

.
0 comments

Int J STD AIDS. 2002 Jul;13(7):508-9.

'Skin popping' ulceration in an HIV patient. Successful treatment with
antiretroviral drugs and stanozolol.

Redondo P, Molano E, Lloret P, Bauza A.

Departments of Dermatology and Internal Medicine, University Clinic of Navarra,
School of Medicine, Pamplona, Spain
.

Skin popping refers to the practice of injecting drugs beneath the skin without
concern for vascular access. We describe a male HIV seropositive injecting-drug
user with chronic cutaneous ulcerations on the legs at sites of skin popping.
Treatment with antiretroviral drugs and stanozolol was associated with a striking
clinical improvement of the ulcer in two weeks. The mechanism of action,
improvement of immune function by the antiretroviral treatment or activity of
stanozolol on collagen and transforming growth factor-beta1 synthesis, remains
unknown.